Home > News > featured news > Aesthetics Biomedical® Announces Collaboration with U.S. Dermatology Partners Offering Consumers Luxury Experiential Aesthetic Treatments

MedTech

Aesthetics Biomedical® Announces Collaboration with U.S. Dermatology Partners Offering Consumers Luxury Experiential Aesthetic Treatments

Aesthetics Biomedical® Inc. | October 07, 2021

Aesthetics Biomedical® Inc. (ABM), is pleased to announce their long-term partnership with U.S. Dermatology Partners, the largest physician-led dermatology practice in the United States.

With years of experience and more than 90+ locations throughout Arizona, Colorado, Kansas, Maryland, Missouri, Oklahoma, Texas, and Virginia, U.S. Dermatology Partners combines the personal level of care found in private dermatology practices with the benefits of a network of physician experts working closely together. As a result, U.S. Dermatology Partners can provide premier medical and cosmetic dermatological care, along with the latest technology, treatments, and management support.

Striving to innovate, generate solid clinical and laboratory research, and to enrich the physician as well as the patient experience are principles that Aesthetics Biomedical® was founded on. It is these foundational principles that have led to our synergy with U.S. Dermatology Partners.

- Chief Executive Officer & Founder, MaryAnn Guerra

U.S. Dermatology Partners, a pinnacle network of specialty experts found a lifetime partner in excellence and innovation with Aesthetics Biomedical®. Beginning in 2021, U.S. Dermatology Partners installed Vivace® into four initial practices. A pilot project between the two organizations launched the partnership that resulted in over 170 consumer treatments being sold within the first four weeks. U.S. Dermatology Partners and ABM marketed the Vivace Experience® concept with the objective of delivering an immediate ROI supporting the purchase of the initial device for the organization. Vivace® is a primary driver expected to positively impact U.S. Dermatology Partners' market growth exponentially and rapidly, already generating significant revenue in six locations across the US, in under six (6) months. Having access to ongoing knowledge and clinical data is critical to U.S. Dermatology Partners physicians who are committed to continuous and consistent superior patient care.

 U.S. Dermatology Partners is thrilled to be collaborating with Aesthetics Biomedical® to bring the Vivace Experience® to our patients and our growing network to Aesthetics Biomedical®. We expect the innovative technology and outstanding results that Vivace offers will be well-received by both our physicians and patients and will provide another opportunity to deliver superior care to the communities we serve.

- U.S. Dermatology Partners Chief Executive Officer Paul Singh

Vivace® is a minimally invasive, FDA-cleared, radiofrequency microneedling treatment that stimulates the natural production of collagen and has been shown by physicians to be effective in alleviating facial wrinkles, fine lines, and tightening the face and neck. Aesthetics Biomedical's Vivace® is currently offered in multiple U.S. Dermatology Partners practices across 50% of the markets nationwide with rapid expansion plans in Q4. ABM will help to drive U.S. Dermatology Partners's practice success with superior technology, devices, and products supported by science, customer-focused market recognition, rigorous and continuing education, and strong continuous return on investment.

Both organizations are aligned in their commitment to excellence and share a common goal for elevating the consumer experience at the forefront of the partnership.

ABOUT AESTHETICS BIOMEDICAL
Aesthetics Biomedical® Inc., headquartered in Phoenix, Ariz., is committed to the development and distribution of novel aesthetic devices, products, and services in the global market. Aesthetics Biomedical's innovation center is a leader in breakthrough technologies and combination therapies for its clients, physician network, and the aesthetic arena, creating novel patient treatment experiences that benefit from ongoing research, approved clinical indications for use, as well as a personalized approach designed for consumer benefit. 

ABOUT U.S. DERMATOLOGY PARTNERS
As one of the largest physician-owned dermatology practices in the country, U.S. Dermatology Partners patients not only have access to general medical, surgical, and cosmetic skin treatment through its coordinated care network, but also benefit from the practice's strong dermatology subspecialty thought leaders and medical advisory board. To be the best partners to its patients, U.S. Dermatology Partners is fervently focused on providing the highest level of patient-first care, and its team, therefore, includes recognized national leaders in areas such as clinical research, psoriasis, and Mohs Surgery.

Spotlight

More featured news

Spotlight

Related News

MedTech, AI

FOXO Technologies™ Collaborates with DataRobot to Pave the Way for AI-Driven Epigenetic Biomarker Research in Human Longevity

Businesswire | August 18, 2023

FOXO Technologies Inc. a leader in the field of commercializing epigenetic biomarker technology, has advanced in its mission to utilize the power of epigenetics and artificial intelligence to generate data-driven insights that promote optimal health and longevity. In collaboration with DataRobot, the leader in Value-Driven AI, FOXO has successfully harnessed the powers of predictive AI and high-throughput automation to estimate factors associated with human longevity using epigenetic biomarkers. Epigenetic biomarkers provide valuable insights into the relationships among health, aging, and human longevity. These biomarkers are developed by leveraging DNA methylation microarray technology, which covers over 860,000 sites on the human genome. By automating the training and evaluation of thousands of models, FOXO is spearheading the commercialization of these revolutionary epigenetic biomarkers, paving the way for advancements in personalized wellness and disease prevention. FOXO's partnership with DataRobot has proven instrumental in its efforts to propel this research forward. By leveraging DataRobot's powerful AI platform, FOXO can efficiently analyze vast amounts of complex data, significantly expediting the identification of key biomarkers. FOXO believes the integration of AI and machine learning will enable FOXO to remain at the forefront of epigenetic research, ensuring unparalleled speed and computational capacity for their clients. Nichole Rigby, Director of Bioinformatics and Data Science at FOXO Technologies, emphasized the significance of their collaboration with DataRobot: “This partnership has been transformative for our research. DataRobot's library of advanced algorithms and extensive automation capabilities have empowered us to rapidly transform DNA methylation data into useful insights, enabling us to develop and deploy software products quickly.” “We believe that with the ability to analyze data at scale, FOXO can uncover critical patterns and associations that hold the potential to reshape healthcare and wellness strategies,” stated CEO of FOXO Technologies, Tyler Danielson. “Our mission is to enhance human health and longevity through innovative technologies. Collaborating with DataRobot has given us the tools to accelerate our efforts, providing crucial insights into the aging process and ultimately enabling us to improve the quality of life for people worldwide.” About FOXO Technologies Inc. (“FOXO”) FOXO Technologies is a pioneering biotechnology company at the forefront of commercializing epigenetic biomarker technology. Their mission is to utilize the power of epigenetics and artificial intelligence to generate data-driven insights that promote optimal health and longevity outcomes for individuals and organizations alike. About DataRobot DataRobot is the leader in Value-Driven AI, a unique and collaborative approach to generative and predictive AI that combines an open platform, deep expertise and broad use-case experience to improve how organizations run, grow and optimize their business. The DataRobot AI Platform is the only complete AI lifecycle platform that interoperates with an organization’s existing investments in data, applications and business processes, and can be deployed on any cloud environment. Global organizations, including 40% of the Fortune 50, rely on DataRobot to drive greater impact and value from AI.

Read More

MedTech, AI

Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus

Globenewswire | August 01, 2023

Evaxion Biotech A/S a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, presents promising results of EVX-B1 at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA. “I am excited to present the impressive results of EVX-B1 at the Gordon Research Conference. The demonstration of full disease protection and complete bacterial clearance marks a significant advancement in the fight against this widespread and often antibiotic-resistant pathogen. With the many previous unsuccessful attempts to develop an effective S. aureus vaccine, EVX-B1 instills renewed hope in the battle against the bacteria,” said Steven Projan, PhD, Scientific Advisor to Evaxion and poster presenter. EVX-B1 has been designed using Evaxion’s proprietary AI technology for vaccine target discovery. The AI technology has enabled the identification of novel S. aureus antigens, paving the way for the development of a vaccine with potential for broad protection against clinically relevant strains. EVX-B1 induces strong immune responses, both cellular and humoral, that translate to a high level of protection in preclinical models for skin infection and sepsis. Importantly, EVX-B1 prevents both the development of disease and effectively eliminates the infection itself. In a 12-month immunogenicity study, EVX-B1 induced high and long-lasting antibody titers. A booster immunization substantially increased the immune response, protecting against S. aureus infection. The EVX-B1 vaccine candidate is ready for non-clinical development, CMC, and subsequent clinical testing. “The remarkable performance of EVX-B1 in state-of-the-art animal models is a testament to our innovative approach and the power of computational target discovery. We are excited about the potential impact this vaccine could have in preventing S. aureus infections, which have long posed significant challenges to global health and where antibiotic resistance is developing fast,” said Birgitte Rønø, Chief Scientific Officer at Evaxion. The poster entitled “EVX-B1: An AI-designed vaccine against Staphylococcus aureus, demonstrating full disease protection and complete bacterial clearance” is presented at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA, taking place from 30th of July to 4th of August this year (https://www.grc.org/staphylococcal-diseases-conference/2023/). About S. aureus infections The S. aureus bacteria are usually harmless but can cause serious infections, leading to sepsis or death. S. aureus is causing severe hospital-acquired infections. Antibiotic-resistant S. aureus, particularly Methicillin-resistant S. aureus (MSRA) infections, are of critical concern and remain a prevention priority. According to the CDC, nearly 120,000 bloodstream infections with 20,000 associated deaths were reported in 2019 (https://www.cdc.gov/mmwr/volumes/68/wr/mm6809e1.htm). The estimated annual economic impact of MRSA on US hospitals alone is $3.2-4.2 billion. About EDEN Our proprietary EDEN platform rapidly identifies novel, highly protective antigens for the use in pathogen-specific prophylactic vaccines against bacteria. Within EDEN, our proprietary algorithms allow us to predict and identify those antigens we believe will trigger a robust, protective immune response against almost any bacterial infectious disease. The input to the AI models is a feature transformation of the protein data set, in which several global and sequence-resolved properties are extracted. These structural and functional features have been selected for their relevance in protein chemistry, immunology, protein structure and ability to guide the network in discriminating protective versus non-protective antigens. About Evaxion   Evaxion Biotech A/S is a pioneering company developing AI-powered immunotherapies. Evaxion’s proprietary and scalable AI technologies decode the human immune system to discover and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has a broad pipeline of candidates, including three personalized cancer immunotherapies. It is located in Hørsholm, Denmark, listed on the Nasdaq New York stock exchange.

Read More

Medical, Industry Outlook

Ginkgo Bioworks and the Government of the Republic of Panama Announce Plans to Establish New Biosecurity Capabilities

PRNewswire | August 07, 2023

Ginkgo Bioworks the leading horizontal platform for cell programming and biosecurity, and the Government of the Republic of Panama's Gorgas Memorial Institute for Health Studies, today announced that they have entered into a Memorandum of Understanding ("MOU") with the intent to develop and implement new biosecurity capabilities in Latin America. Ginkgo, through its biosecurity and public health unit, Concentric by Ginkgo, aims to support the Gorgas Institute as it builds Panama's foundational bioeconomy that will serve not only the country, but also the surrounding region. These efforts will bolster Panama's biosecurity infrastructure, giving the country key tools to detect, identify, and monitor current and future pathogens. It will also be Concentric's first Latin American program, as the company continues to expand operations internationally. As part of the program, Concentric will collaborate with the Gorgas Institute to strengthen their current surveillance infrastructure for COVID-19, as well as other respiratory and enteric pathogens, leveraging Concentric's expertise in wastewater monitoring, lab enablement, and bioinformatics analysis and decision support. The program is expected to operate in strategic locations that can help bolster both national and regional public health and security throughout Panama. These include, but are not limited to, wastewater surveillance in major urban centers like Panama City, as well as at ports-of-entry, including the border crossing in the Darien National Park and Tocumen International Airport (PTY). By establishing these monitoring programs, Panama will become a critical node in Concentric's global network that collects data to help public health and national security officials detect and respond to emerging biological threats. The information captured from these programs is expected to play a key role in strengthening not only Panama's COVID-19 and novel pathogen detection infrastructure, but also provide key data for regional pandemic preparedness. "We're honored to collaborate with the Republic of Panama to strengthen the region's health security capabilities through pathogen threat detection in Panama City and the Darien region," said Matt McKnight, General Manager, Biosecurity at Ginkgo Bioworks. "Robust bio-surveillance in Panama is critical not only for the health of the country, but also for the security of the Western Hemisphere, and I am confident this partnership will strengthen health security in the region and the world." "These detection and monitoring programs are an important aspect of Panama's public health initiatives. We are excited to collaborate with Concentric on these important biosecurity programs," said Dr. Juan Miguel Pascale, General Director of Gorgas Memorial Institute for Health Studies. About Ginkgo Bioworks Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. About the Gorgas Memorial Institute for Health Studies Gorgas Memorial Institute is the national reference laboratory and research institute of Panama, and the support arm of the Ministry of Health. Founded in 1928 in memory of Dr. William C. Gorgas who implemented public health measures that allowed the control of malaria and yellow fever enabling the construction of the Panama Canal, its research has been centered in the study of tropical diseases: leishmaniasis, malaria, yellow fever, Dengue, Zika and Chikungunya among other arbovirosis as well as the surveillance of Influenza and respiratory viruses and endemic agents such as Hantavirus, Venezuelan and Eastern Equine Encephalitis. During the last decade it has also been involved in HIV surveillance and in research of non-communicable diseases in the country.

Read More

MedTech, AI

FOXO Technologies™ Collaborates with DataRobot to Pave the Way for AI-Driven Epigenetic Biomarker Research in Human Longevity

Businesswire | August 18, 2023

FOXO Technologies Inc. a leader in the field of commercializing epigenetic biomarker technology, has advanced in its mission to utilize the power of epigenetics and artificial intelligence to generate data-driven insights that promote optimal health and longevity. In collaboration with DataRobot, the leader in Value-Driven AI, FOXO has successfully harnessed the powers of predictive AI and high-throughput automation to estimate factors associated with human longevity using epigenetic biomarkers. Epigenetic biomarkers provide valuable insights into the relationships among health, aging, and human longevity. These biomarkers are developed by leveraging DNA methylation microarray technology, which covers over 860,000 sites on the human genome. By automating the training and evaluation of thousands of models, FOXO is spearheading the commercialization of these revolutionary epigenetic biomarkers, paving the way for advancements in personalized wellness and disease prevention. FOXO's partnership with DataRobot has proven instrumental in its efforts to propel this research forward. By leveraging DataRobot's powerful AI platform, FOXO can efficiently analyze vast amounts of complex data, significantly expediting the identification of key biomarkers. FOXO believes the integration of AI and machine learning will enable FOXO to remain at the forefront of epigenetic research, ensuring unparalleled speed and computational capacity for their clients. Nichole Rigby, Director of Bioinformatics and Data Science at FOXO Technologies, emphasized the significance of their collaboration with DataRobot: “This partnership has been transformative for our research. DataRobot's library of advanced algorithms and extensive automation capabilities have empowered us to rapidly transform DNA methylation data into useful insights, enabling us to develop and deploy software products quickly.” “We believe that with the ability to analyze data at scale, FOXO can uncover critical patterns and associations that hold the potential to reshape healthcare and wellness strategies,” stated CEO of FOXO Technologies, Tyler Danielson. “Our mission is to enhance human health and longevity through innovative technologies. Collaborating with DataRobot has given us the tools to accelerate our efforts, providing crucial insights into the aging process and ultimately enabling us to improve the quality of life for people worldwide.” About FOXO Technologies Inc. (“FOXO”) FOXO Technologies is a pioneering biotechnology company at the forefront of commercializing epigenetic biomarker technology. Their mission is to utilize the power of epigenetics and artificial intelligence to generate data-driven insights that promote optimal health and longevity outcomes for individuals and organizations alike. About DataRobot DataRobot is the leader in Value-Driven AI, a unique and collaborative approach to generative and predictive AI that combines an open platform, deep expertise and broad use-case experience to improve how organizations run, grow and optimize their business. The DataRobot AI Platform is the only complete AI lifecycle platform that interoperates with an organization’s existing investments in data, applications and business processes, and can be deployed on any cloud environment. Global organizations, including 40% of the Fortune 50, rely on DataRobot to drive greater impact and value from AI.

Read More

MedTech, AI

Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus

Globenewswire | August 01, 2023

Evaxion Biotech A/S a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, presents promising results of EVX-B1 at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA. “I am excited to present the impressive results of EVX-B1 at the Gordon Research Conference. The demonstration of full disease protection and complete bacterial clearance marks a significant advancement in the fight against this widespread and often antibiotic-resistant pathogen. With the many previous unsuccessful attempts to develop an effective S. aureus vaccine, EVX-B1 instills renewed hope in the battle against the bacteria,” said Steven Projan, PhD, Scientific Advisor to Evaxion and poster presenter. EVX-B1 has been designed using Evaxion’s proprietary AI technology for vaccine target discovery. The AI technology has enabled the identification of novel S. aureus antigens, paving the way for the development of a vaccine with potential for broad protection against clinically relevant strains. EVX-B1 induces strong immune responses, both cellular and humoral, that translate to a high level of protection in preclinical models for skin infection and sepsis. Importantly, EVX-B1 prevents both the development of disease and effectively eliminates the infection itself. In a 12-month immunogenicity study, EVX-B1 induced high and long-lasting antibody titers. A booster immunization substantially increased the immune response, protecting against S. aureus infection. The EVX-B1 vaccine candidate is ready for non-clinical development, CMC, and subsequent clinical testing. “The remarkable performance of EVX-B1 in state-of-the-art animal models is a testament to our innovative approach and the power of computational target discovery. We are excited about the potential impact this vaccine could have in preventing S. aureus infections, which have long posed significant challenges to global health and where antibiotic resistance is developing fast,” said Birgitte Rønø, Chief Scientific Officer at Evaxion. The poster entitled “EVX-B1: An AI-designed vaccine against Staphylococcus aureus, demonstrating full disease protection and complete bacterial clearance” is presented at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA, taking place from 30th of July to 4th of August this year (https://www.grc.org/staphylococcal-diseases-conference/2023/). About S. aureus infections The S. aureus bacteria are usually harmless but can cause serious infections, leading to sepsis or death. S. aureus is causing severe hospital-acquired infections. Antibiotic-resistant S. aureus, particularly Methicillin-resistant S. aureus (MSRA) infections, are of critical concern and remain a prevention priority. According to the CDC, nearly 120,000 bloodstream infections with 20,000 associated deaths were reported in 2019 (https://www.cdc.gov/mmwr/volumes/68/wr/mm6809e1.htm). The estimated annual economic impact of MRSA on US hospitals alone is $3.2-4.2 billion. About EDEN Our proprietary EDEN platform rapidly identifies novel, highly protective antigens for the use in pathogen-specific prophylactic vaccines against bacteria. Within EDEN, our proprietary algorithms allow us to predict and identify those antigens we believe will trigger a robust, protective immune response against almost any bacterial infectious disease. The input to the AI models is a feature transformation of the protein data set, in which several global and sequence-resolved properties are extracted. These structural and functional features have been selected for their relevance in protein chemistry, immunology, protein structure and ability to guide the network in discriminating protective versus non-protective antigens. About Evaxion   Evaxion Biotech A/S is a pioneering company developing AI-powered immunotherapies. Evaxion’s proprietary and scalable AI technologies decode the human immune system to discover and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has a broad pipeline of candidates, including three personalized cancer immunotherapies. It is located in Hørsholm, Denmark, listed on the Nasdaq New York stock exchange.

Read More

Medical, Industry Outlook

Ginkgo Bioworks and the Government of the Republic of Panama Announce Plans to Establish New Biosecurity Capabilities

PRNewswire | August 07, 2023

Ginkgo Bioworks the leading horizontal platform for cell programming and biosecurity, and the Government of the Republic of Panama's Gorgas Memorial Institute for Health Studies, today announced that they have entered into a Memorandum of Understanding ("MOU") with the intent to develop and implement new biosecurity capabilities in Latin America. Ginkgo, through its biosecurity and public health unit, Concentric by Ginkgo, aims to support the Gorgas Institute as it builds Panama's foundational bioeconomy that will serve not only the country, but also the surrounding region. These efforts will bolster Panama's biosecurity infrastructure, giving the country key tools to detect, identify, and monitor current and future pathogens. It will also be Concentric's first Latin American program, as the company continues to expand operations internationally. As part of the program, Concentric will collaborate with the Gorgas Institute to strengthen their current surveillance infrastructure for COVID-19, as well as other respiratory and enteric pathogens, leveraging Concentric's expertise in wastewater monitoring, lab enablement, and bioinformatics analysis and decision support. The program is expected to operate in strategic locations that can help bolster both national and regional public health and security throughout Panama. These include, but are not limited to, wastewater surveillance in major urban centers like Panama City, as well as at ports-of-entry, including the border crossing in the Darien National Park and Tocumen International Airport (PTY). By establishing these monitoring programs, Panama will become a critical node in Concentric's global network that collects data to help public health and national security officials detect and respond to emerging biological threats. The information captured from these programs is expected to play a key role in strengthening not only Panama's COVID-19 and novel pathogen detection infrastructure, but also provide key data for regional pandemic preparedness. "We're honored to collaborate with the Republic of Panama to strengthen the region's health security capabilities through pathogen threat detection in Panama City and the Darien region," said Matt McKnight, General Manager, Biosecurity at Ginkgo Bioworks. "Robust bio-surveillance in Panama is critical not only for the health of the country, but also for the security of the Western Hemisphere, and I am confident this partnership will strengthen health security in the region and the world." "These detection and monitoring programs are an important aspect of Panama's public health initiatives. We are excited to collaborate with Concentric on these important biosecurity programs," said Dr. Juan Miguel Pascale, General Director of Gorgas Memorial Institute for Health Studies. About Ginkgo Bioworks Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. About the Gorgas Memorial Institute for Health Studies Gorgas Memorial Institute is the national reference laboratory and research institute of Panama, and the support arm of the Ministry of Health. Founded in 1928 in memory of Dr. William C. Gorgas who implemented public health measures that allowed the control of malaria and yellow fever enabling the construction of the Panama Canal, its research has been centered in the study of tropical diseases: leishmaniasis, malaria, yellow fever, Dengue, Zika and Chikungunya among other arbovirosis as well as the surveillance of Influenza and respiratory viruses and endemic agents such as Hantavirus, Venezuelan and Eastern Equine Encephalitis. During the last decade it has also been involved in HIV surveillance and in research of non-communicable diseases in the country.

Read More

More featured news